$VYNE
VYNE Therapeutics Inc. Stock $vyne

$vyne Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000156604420000011 Filed on August 06, 2020

Income Statement

Concept	2020 Q2	2019 Q4	2019 Q2
Revenue	$11.69M	$135.0K	$0.00
YoY Change			-100.0%
Cost Of Revenue	$178.9M	$0.00	$19.36M
YoY Change	823.94%
Gross Profit	-$167.2M	$135.0K	-$19.36M
YoY Change	763.56%
Gross Profit Margin	-1430.33%	100.0%
Selling, General & Admin	$26.46M	$10.17M	$6.803M
YoY Change	288.93%	202.68%	120.16%
% of Gross Profit		7533.33%
Research & Development	$13.12M	$11.76M	$12.56M
YoY Change	4.48%	-22.02%	-22.62%
% of Gross Profit		8711.11%
Depreciation & Amortization	$100.0K	-$200.0K	$80.00K
YoY Change	25.0%	-2100.0%
% of Gross Profit		-148.15%
Operating Expenses	$39.58M	$21.93M	$17.22M
YoY Change	129.89%	18.93%	-10.87%
Operating Profit	-$167.2M	-$37.43M	-$19.36M
YoY Change	763.56%		111.04%
Interest Expense	$1.070M	$433.0K	$739.0K
YoY Change	44.79%	-48.82%	-10.53%
% of Operating Profit
Other Income/Expense, Net	$548.0K		$739.0K
YoY Change	-25.85%		-10.53%
Pretax Income	-$167.7M	-$21.50M	-$18.99M
YoY Change	782.95%	22.23%	127.46%
Income Tax	-$259.0K		$0.00
% Of Pretax Income
Net Earnings	-$167.4M	-$21.50M	-$18.99M
YoY Change	781.59%	22.19%	127.54%
Net Earnings / Revenue	-1432.58%	-15924.44%
Basic Earnings Per Share	-$4.83
Diluted Earnings Per Share	-$4.83	-$3.560M	-$775.1K
COMMON SHARES
Basic Shares Outstanding	34.66M shares	23.98M
Diluted Shares Outstanding	34.66M shares

Balance Sheet

Concept	2020 Q2	2019 Q4	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$99.12M	$60.44M	$109.4M
YoY Change	-9.4%	-55.66%	-28.87%
Cash & Equivalents	$96.51M	$43.76M	$39.09M
Short-Term Investments	$2.609M	$16.68M	$44.40M
Other Short-Term Assets	$6.600M	$19.10M	$3.700M
YoY Change	78.38%	478.79%	60.87%
Inventory	$5.801M	$1.356M
Prepaid Expenses
Receivables	$6.407M	$135.0K
Other Receivables	$4.000M	$0.00
Total Short-Term Assets	$119.3M	$76.41M	$113.1M
YoY Change	5.45%	-45.22%	-27.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.811M	$2.885M	$128.0K
YoY Change	2096.09%	1876.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.200M	$166.0K	$100.0K
YoY Change	6100.0%	-44.67%	-67.32%
Total Long-Term Assets	$11.55M	$4.745M	$1.257M
YoY Change	819.01%	1008.64%	-88.25%
TOTAL ASSETS
Total Short-Term Assets	$119.3M	$76.41M	$113.1M
Total Long-Term Assets	$11.55M	$4.745M	$1.257M
Total Assets	$130.8M	$81.16M	$114.4M
YoY Change	14.39%	-42.0%	-31.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.00M	$3.771M	$4.704M
YoY Change	112.59%	14.62%	-7.76%
Accrued Expenses	$8.812M	$3.381M	$6.487M
YoY Change	35.84%	-45.94%	96.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.23M	$29.33M	$11.91M
YoY Change	103.53%	207.27%	38.44%
LONG-TERM LIABILITIES
Long-Term Debt	$32.92M	$32.73M	$0.00
YoY Change
Other Long-Term Liabilities	$2.200M	$1.500M	$300.0K
YoY Change	633.33%	21328.57%	200.0%
Total Long-Term Liabilities	$35.08M	$34.26M	$300.0K
YoY Change	11594.0%	489300.0%	200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.23M	$29.33M	$11.91M
Total Long-Term Liabilities	$35.08M	$34.26M	$300.0K
Total Liabilities	$59.31M	$63.58M	$12.21M
YoY Change	385.9%	565.73%	40.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$518.3M	-$310.6M	-$146.0M
YoY Change	255.03%	180.73%
Common Stock	$17.00K	$1.000K	$248.2M
YoY Change	-99.99%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$71.53M	$17.58M	$60.38M
YoY Change
Total Liabilities & Shareholders Equity	$130.8M	$81.16M	$114.4M
YoY Change	14.39%	-42.0%	-31.47%

Cashflow Statement

Concept	2020 Q2	2019 Q4	2019 Q2
OPERATING ACTIVITIES
Net Income	-$167.4M	-$21.50M	-$18.99M
YoY Change	781.59%	22.19%	127.54%
Depreciation, Depletion And Amortization	$100.0K	-$200.0K	$80.00K
YoY Change	25.0%	-2100.0%
Cash From Operating Activities	-$35.86M	-$13.95M	-$12.72M
YoY Change	181.92%	-16.01%	0.55%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	$850.0K	-$310.0K
YoY Change	-77.42%	-4350.0%
Acquisitions
YoY Change
Other Investing Activities	$21.20M	$4.690M	$33.09M
YoY Change	-35.93%	-215.8%	330.86%
Cash From Investing Activities	$21.13M	$5.530M	$32.77M
YoY Change	-35.52%	-235.87%	326.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	53.61M	-22.96M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-35.86M	-13.95M	-12.72M
Cash From Investing Activities	21.13M	5.530M	32.77M
Cash From Financing Activities	53.61M	-22.96M	0.000
Net Change In Cash	38.88M	-31.38M	20.05M
YoY Change	93.92%	51.74%	-505.87%
FREE CASH FLOW
Cash From Operating Activities	-$35.86M	-$13.95M	-$12.72M
Capital Expenditures	-$70.00K	$850.0K	-$310.0K
Free Cash Flow	-$35.79M	-$14.80M	-$12.41M
YoY Change	188.4%	-10.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001566044
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38356
	dei	Entity Registrant Name EntityRegistrantName	MENLO THERAPEUTICS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3757789
	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 U.S. Highway 22, Suite 204
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
	dei	City Area Code CityAreaCode	800
	dei	Local Phone Number LocalPhoneNumber	755-7936
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
	dei	Trading Symbol TradingSymbol	MNLO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	us-gaap	Assets Assets	81159000	USD
CY2020Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9952000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8812000	USD
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	167690615	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96511000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43759000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	855000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	825000	USD
CY2020Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	0	USD
CY2019Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	12102000	USD
CY2020Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2609000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16246000	USD
CY2020Q2	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	435000	USD
CY2019Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	434000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6407000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	135000	USD
CY2020Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4000000	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2672000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1557000	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	19352000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	5801000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	1356000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2885000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	119290000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	76414000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2811000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2558000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1694000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	6183000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	166000	USD
CY2020Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	11552000	USD
CY2019Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	4745000	USD
CY2020Q2	us-gaap	Assets Assets	130842000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3381000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5231000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1245000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1092000	USD
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4081000	USD
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	142000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	270000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	24232000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29326000	USD
CY2020Q2	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	403000	USD
CY2019Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	424000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1308000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	653000	USD
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	32915000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	32725000	USD
CY2020Q2	us-gaap	Other Liabilities OtherLiabilities	456000	USD
CY2019Q4	us-gaap	Other Liabilities OtherLiabilities	456000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	34258000	USD
CY2020Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	35082000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	59314000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	63584000	USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	167683814	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	167683814	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36480314	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36480314	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	589812000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	328154000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-518301000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-310587000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	71528000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17575000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	130842000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81159000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11688000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13438000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	308000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	216000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	487000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13119000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12556000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29072000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23404000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26459000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6803000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	51874000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12147000	USD
CY2020Q2	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	54345000	USD
CY2019Q2	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	54345000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2020Q2	mnlo	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84726000	USD
CY2019Q2	mnlo	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
	mnlo	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84726000	USD
	mnlo	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	178865000	USD
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	19359000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	220504000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	35551000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-167177000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-19359000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-207066000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35243000	USD
CY2020Q2	mnlo	Financial Income Net FinancialIncomeNet	564000	USD
CY2019Q2	mnlo	Financial Income Net FinancialIncomeNet	468000	USD
	mnlo	Financial Income Net FinancialIncomeNet	1292000	USD
	mnlo	Financial Income Net FinancialIncomeNet	1004000	USD
CY2020Q2	mnlo	Financial Expenses FinancialExpenses	1086000	USD
CY2019Q2	mnlo	Financial Expenses FinancialExpenses	102000	USD
	mnlo	Financial Expenses FinancialExpenses	2158000	USD
	mnlo	Financial Expenses FinancialExpenses	134000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-167699000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18993000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-207932000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34373000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-259000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-259000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-176000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-167440000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-18993000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-207673000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34197000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.21
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.19
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	2.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.35
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	138653000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	97999000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90627000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	97954000	shares
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-167440000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-18993000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-207673000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34197000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	43000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	40000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	3000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	4000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	0	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-13000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	0	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	2000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	40000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	42000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-167400000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19002000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-207678000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34155000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	92182000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34155000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2337000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	60382000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17575000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-207678000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	260000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	12527000	USD
	mnlo	Deemed Dividend To Warrants Holders Due To Warrant Modification DeemedDividendToWarrantsHoldersDueToWarrantModification	0	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1387000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	60382000	USD
	mnlo	Share Based Payment Modification Of Terms Incremental Compensation Modification Of Terms Incremental Compensation Cost Reclassified Adjustment ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment	975000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3903000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53649000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	196170000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	71528000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	77995000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19002000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	69535000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-167400000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-43000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	10768000	USD
CY2020Q2	mnlo	Share Based Payment Modification Of Terms Incremental Compensation Modification Of Terms Incremental Compensation Cost Reclassified Adjustment ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment	-657000	USD
CY2020Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3903000	USD
	mnlo	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84726000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53649000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	104362000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	71528000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-207673000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34197000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	187000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	163000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	54345000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
	mnlo	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	142000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	358000	USD
	mnlo	Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits	-21000	USD
	mnlo	Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits	42000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12527000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2337000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	833000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9807000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-246000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	6026000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10908000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2374000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4445000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88070000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29361000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	113000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	454000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	16048000	USD
	mnlo	Proceeds From Business Merger ProceedsFromBusinessMerger	38641000	USD
	mnlo	Proceeds From Business Merger ProceedsFromBusinessMerger	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	48577000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	57014000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	87105000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	40512000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53646000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53746000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	52781000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11169000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44584000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28118000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97366000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39335000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96511000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39085000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	855000	USD
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	250000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97366000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39335000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	4000	USD
	us-gaap	Stock Issued1 StockIssued1	163000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1120000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	867000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1120000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	850000	USD
	mnlo	Interest Received InterestReceived	298000	USD
	mnlo	Interest Received InterestReceived	666000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1946000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	5827000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	117270000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	111443000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
	mnlo	Non Cash Acquisition Of Business Cash Acquired NonCashAcquisitionOfBusinessCashAcquired	38641000	USD
	mnlo	Non Cash Acquisition Of Business Cash Acquired NonCashAcquisitionOfBusinessCashAcquired	0	USD
	mnlo	Non Cash Acquisition Of Business Net Assets After Cash Acquired NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired	72802000	USD
	mnlo	Non Cash Acquisition Of Business Net Assets After Cash Acquired NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF OPERATIONS<div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Menlo Therapeutics Inc. (the “Company,” “Menlo” or the “combined company”) is a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as one business segment.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Reverse Merger</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 10, 2019, the Company, Foamix Pharmaceuticals Ltd. (“Foamix”) and Giants Merger Subsidiary Ltd. (“Merger Sub”), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the “Merger”) on March 9, 2020 (the “Effective Date”).</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For accounting purposes, the Merger is treated as a “reverse acquisition” under generally accepted accounting principles in the United States (“U.S. GAAP”) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company’s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See “Note 3 – Business Combination” for more information on the Merger.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Products, Product Candidates and Licenses</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, in January 2020, Foamix launched AMZEEQ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (minocycline) topical foam, 4% (“AMZEEQ”), a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (minocycline) topical form, 1.5% (formerly FMX103, "ZILXI"), for the treatment of inflammatory lesions of rosacea in adults. AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMZEEQ and ZILXI utilize the Company’s proprietary Molecule Stabilizing Technology (MST)</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that is also being used in the development of the Company’s other product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. The Company has begun preparations to conduct an end-of-Phase II meeting with the FDA before the end of 2020.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to pursue serlopitant. As a result, the Company recorded a full impairment charge related to the IPR&D and Goodwill assets in its unaudited condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2020. See "Note 3 - Business Combination" for more information.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is actively pursuing opportunities to out-license its products and product candidates to third parties for development and commercialization outside the United States, and recently entered into a license agreement with Cutia Therapeutics (HK) Limited (“Cutia”). See "Note 4 - Revenue Recognition." The Company has also licensed certain technology under development and licensing agreements to various pharmaceutical companies for development of certain products combining the Company’s foam technology with the licensee’s proprietary drugs.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company launched AMZEEQ in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company’s activities prior to the commercial launch of AMZEEQ had primarily consisted of </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">developing product candidates, raising capital and performing research and development activities. Since inception, the Company has incurred losses and negative cash flows from operations. For the six months ended June 30, 2020, the Company incurred a net loss of $207.7 million and used $88.1 million of cash in operations. As of June 30, 2020, the Company had cash, cash equivalents and investments of $100.4 million and an accumulated deficit of $518.3 million.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company does not successfully commercialize AMZEEQ, ZILXI or any of its future product candidates, it may be unable to achieve profitability. Accordingly, the Company may be required to obtain further funding through public or private debt or equity offerings, or other arrangements. Adequate additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce or eliminate its research and development programs or commercialization and manufacturing efforts. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, the Company was focused on the development and commercialization of serlopitant. Following the receipt of the results of the Phase 3 clinical trials evaluating serlopitant for the treatment of PN and the impact of the COVID-19 pandemic, the Company has revised its operating plan to focus on the commercialization of AMZEEQ, ZILXI and its other topical minocycline product candidates. The Company does not currently intend to pursue serlopitant further. In addition, the revised operating plan reflects prudent resource prioritization and allocation management, including the rationalization of research and development spend to focus on existing product candidates.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its existing cash, cash equivalents and investments as of June 30, 2020 and projected cash flows from revenues and the funds that the Company is entitled to receive under the license agreement with Cutia Therapeutics (HK) Limited ("Cutia"), will provide sufficient resources to fund its current ongoing needs for at least the next 12 months from the issuance of these financial statements, though there may be need for additional financing activity if the on-going COVID-19 pandemic continues for an extended duration and as the Company continues to grow.</span></div>As a result of the COVID-19 pandemic, the Company suspended the vast majority of its in-person interactions by its customer-facing professionals in healthcare settings and have engaged with these customers remotely as the Company seeks to continue to support healthcare professionals and patient care. During the second quarter of 2020, the Company began limited in-person customer meetings and interactions in certain regions, consistent with local government mandates. However, during the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures. As a result of the negative impact on the Company's product sales, the Company and its lenders amended the minimum net revenue covenant in the Amended and Restated Credit Agreement. See "Note 8 - Long-Term Debt." The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict. An extended duration of the COVID-19 pandemic could continue to negatively impact sales of AMZEEQ, and any future sales of ZILXI, and have a material adverse effect on the Company's liquidity, as well as the Company's ability to remain in compliance with the minimum net revenue covenants contained in the Company's loan documents.
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segments
	us-gaap	Net Income Loss NetIncomeLoss	-207700000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88100000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	100400000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-518300000	USD
	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company’s estimates.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which the pandemic impacts worldwide macroeconomic conditions, including interest rates, employment rates and health insurance coverage; the speed of the anticipated recovery; and governmental and business reactions to the pandemic. For the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures due to the pandemic. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition. The Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information). The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.</span></div>
CY2020Q2	mnlo	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	mnlo	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	1.8006
CY2020Q2	mnlo	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	mnlo	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	mnlo	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2020Q2	mnlo	Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders PostMergerParentOwnershipByPreMergerSubsidiaryShareholders	0.82
CY2020Q2	mnlo	Post Merger Parent Ownership By Pre Merger Parent Stockholders PostMergerParentOwnershipByPreMergerParentStockholders	0.18
CY2020Q1	mnlo	Business Combination Acquiree Common Stock Rights Converted To Common Stock BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock	19600000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4000000.0	USD
CY2020Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4000000.0	USD
CY2020Q2	mnlo	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	mnlo	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	mnlo	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2020Q2	mnlo	Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders PostMergerParentOwnershipByPreMergerSubsidiaryShareholders	0.82
CY2020Q2	mnlo	Post Merger Parent Ownership By Pre Merger Parent Stockholders PostMergerParentOwnershipByPreMergerParentStockholders	0.18
CY2020Q2	mnlo	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84700000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	104400000	USD
CY2020Q2	mnlo	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2020Q2	us-gaap	Share Price SharePrice	1.40
CY2020Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	11688000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-205082000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-69547000	USD
CY2020Q2	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	0	USD
	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	0	USD
CY2020Q2	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	7594000	USD
	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	19637000	USD
CY2019Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	0	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	13438000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	308000	USD
CY2020Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-167441000	USD
CY2019Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-35470000	USD
CY2020Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.21
CY2020Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.21
CY2019Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.59
CY2019Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.59
CY2020Q2	mnlo	Revenue Recognition Distribution Trade Discounts And Allowances RevenueRecognitionDistributionTradeDiscountsAndAllowances	5900000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	16680000	USD
CY2020Q2	mnlo	Adjustments To Supplemental Proforma Transaction Costs AdjustmentsToSupplementalProformaTransactionCosts	0	USD
CY2019Q2	mnlo	Adjustments To Supplemental Proforma Transaction Costs AdjustmentsToSupplementalProformaTransactionCosts	0	USD
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.23
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.23
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.16
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.16
	mnlo	Adjustments To Supplemental Proforma Transaction Costs AdjustmentsToSupplementalProformaTransactionCosts	14931000	USD
	mnlo	Adjustments To Supplemental Proforma Transaction Costs AdjustmentsToSupplementalProformaTransactionCosts	0	USD
CY2020Q2	mnlo	Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation	0	USD
CY2019Q2	mnlo	Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation	0	USD
	mnlo	Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation	7199000	USD
	mnlo	Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation	0	USD
CY2020Q2	mnlo	Adjustments To Supplemental Proforma Combined Results Of Operations AdjustmentsToSupplementalProformaCombinedResultsOfOperations	0	USD
CY2019Q2	mnlo	Adjustments To Supplemental Proforma Combined Results Of Operations AdjustmentsToSupplementalProformaCombinedResultsOfOperations	0	USD
	mnlo	Adjustments To Supplemental Proforma Combined Results Of Operations AdjustmentsToSupplementalProformaCombinedResultsOfOperations	22130000	USD
	mnlo	Adjustments To Supplemental Proforma Combined Results Of Operations AdjustmentsToSupplementalProformaCombinedResultsOfOperations	0	USD
	mnlo	Revenue Recognition Distribution Trade Discounts And Allowances RevenueRecognitionDistributionTradeDiscountsAndAllowances	14100000	USD
CY2020Q2	mnlo	Estimate Of Product Return Rate Minimum EstimateOfProductReturnRateMinimum	0.02
CY2020Q2	mnlo	Estimate Of Product Return Rate Maximum EstimateOfProductReturnRateMaximum	0.03
CY2020Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4000000.0	USD
CY2020Q2	us-gaap	Marketable Securities MarketableSecurities	2609000	USD
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	16680000	USD
CY2020Q2	mnlo	Derivate Costs For Year DerivateCostsForYear	0	USD
	mnlo	Derivative Maximum Term Of Contract DerivativeMaximumTermOfContract	P1Y
CY2020Q2	us-gaap	Derivative Amount Of Hedged Item DerivativeAmountOfHedgedItem	0	USD
CY2020Q2	mnlo	Foreign Exchange Risk Lien On Marketable Securities For Bank Guarantees Granted For Hedging Transactions ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions	300000	USD
CY2020Q2	mnlo	Foreign Exchange Risk Lien On Checking Account For Bank Guarantees Granted For Hedging Transactions ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions	300000	USD
CY2020Q2	us-gaap	Short Term Investments ShortTermInvestments	2609000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2018000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2018000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	15660000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	15656000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	36400000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	33000000.0	USD
CY2020Q2	us-gaap	Restricted Investments RestrictedInvestments	400000	USD
CY2019Q4	us-gaap	Restricted Investments RestrictedInvestments	400000	USD
CY2020Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3387000	USD
CY2020Q2	mnlo	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2019Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	500000	USD
CY2020Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	954000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2020Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1460000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	856000	USD
CY2020Q2	us-gaap	Inventory Gross InventoryGross	5801000	USD
CY2019Q4	us-gaap	Inventory Gross InventoryGross	1356000	USD
CY2020Q1	mnlo	Stock Issued During Period Shares Warrant Exchange StockIssuedDuringPeriodSharesWarrantExchange	651640	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.53
CY2019Q3	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1100000	USD
CY2020Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1000000.0	USD
CY2020Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	100000	USD
CY2020Q2	mnlo	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	mnlo	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
	us-gaap	Interest Expense Debt InterestExpenseDebt	1900000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000	USD
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	300000	USD
	mnlo	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue	11400000	USD
	mnlo	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue	3700000	USD
CY2020Q2	mnlo	Effective Exchange Ratio EffectiveExchangeRatio	1.8006
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10768000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1388000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12527000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2337000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
	mnlo	Vehicle Lease Prepayment Period VehicleLeasePrepaymentPeriod	P3M
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1267000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	993000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	768000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	90000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3118000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	565000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2553000	USD
CY2020Q2	mnlo	Restricted Investments To Secure Lease Agreements RestrictedInvestmentsToSecureLeaseAgreements	700000	USD

Files In Submission

Name	View Source	Status
0001566044-20-000011-index-headers.html	Edgar Link	pending
0001566044-20-000011-index.html	Edgar Link	pending
0001566044-20-000011.txt	Edgar Link	pending
0001566044-20-000011-xbrl.zip	Edgar Link	pending
ex101cutia-licenseagre.htm	Edgar Link	pending
ex102agreementno1toarc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mnlo-20200630.htm	Edgar Link	pending
mnlo-20200630.xsd	Edgar Link	pending
mnlo-20200630xexx311.htm	Edgar Link	pending
mnlo-20200630xexx312.htm	Edgar Link	pending
mnlo-20200630xexx321.htm	Edgar Link	pending
mnlo-20200630xexx322.htm	Edgar Link	pending
mnlo-20200630_cal.xml	Edgar Link	unprocessable
mnlo-20200630_def.xml	Edgar Link	unprocessable
mnlo-20200630_htm.xml	Edgar Link	completed
mnlo-20200630_lab.xml	Edgar Link	unprocessable
mnlo-20200630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VYNE
VYNE Therapeutics Inc. Stock $vyne

2020 Q2 Form 10-Q Financial Statement

#000156604420000011 Filed on August 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE VYNE Therapeutics Inc. Stock $vyne

2020 Q2 Form 10-Q Financial Statement

#000156604420000011 Filed on August 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE
VYNE Therapeutics Inc. Stock $vyne